 In this narrative review, we summarize the current evidence on the efficacy of the FreeStyle Libre with regard to HbA 1c , hypoglycaemia and quality of life from randomized and observational studies.
Introduction
Type 1 diabetes is a demanding lifelong condition. It requires individuals to measure blood glucose multiple times a day, facilitating insulin dose adjustment in the unrelenting endeavour to achieve normoglycaemia and minimize the future risk of micro-and macrovascular complications [1] . Despite major progress in the care of people living with Type 1 diabetes, many fail to achieve modern glycaemic targets. A key barrier to achieving near normal glucose levels is this need for frequent finger-stick blood glucose monitoring, perhaps only second to the risk and fear of hypoglycaemia [2] . Pain and inconvenience are recognized reasons for non-adherence to self-monitoring of blood glucose [3, 4] .
Remarkably, self-monitoring of blood glucose (SMBG) has only been an option since the 1970s [5] . Its introduction was met with controversy. Despite Sonksen reporting 'insulin dosage and type were found to be much easier and more predictable than with urine-glucose analysis…hypoglycaemic episodes were less frequent, 70% of patients preferred blood-tests to urine tests and 92% would like to buy their own meter if the price was right', it was not until the 1980s that uptake became more widespread. Blood glucose monitoring is now accepted as the standard of care, with the National Institute for Health and Care Excellence (NICE; NG17) recommending four to 10 measurements per day [6] .
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In 1999, MiniMed received US Food and Drug Administration approval for the first retrospective continuous glucose monitoring (CGM) device in the USA [7] . Since then, a number of retrospective and real-time CGM options have been introduced, including MiniMed iPro, Enlite 2, Enlite Enhanced, Enlite 3 (Medtronic Inc, Northridge, CA, USA), DexCom Short Term Sensor, Dexcom 3, 7, Gen 4 and 5 (Dexcom Inc, San Diego, CA, USA), and Navigator I and II (Abbott Diabetes Care, Alameda, CA, USA). These devices have been evaluated in a range of studies, which have shown that consistent use of real-time CGM is associated with improvements in HbA 1c and reductions in hypoglycaemia [8, 9] . However, widespread adoption of these devices has been hampered by several factors including cost, accuracy of earlier devices and user acceptability.
In 2014, a new category of device was introduced: the FreeStyle Libre Flash Glucose Monitoring System (Abbott Diabetes Care, Alameda, CA). The FreeStyle Libre device is a white disc, worn on the arm for 14 days. As implied by the term 'flash glucose monitoring' the user can obtain glucose results instantly by scanning the glucose sensor with the reader, or their mobile phone, producing real-time on-demand glucose data. A recent International Consensus on CGM has coined the term 'intermittently viewed CGM' to describe flash glucose monitoring [10] . While both real-time CGM and the FreeStyle Libre will allow users to monitor interstitial glucose levels, only real-time CGM will trigger an alarm to alert users to the potential risk of hypoglycaemia or hyperglycaemia. With the FreeStyle Libre, such trends can only be viewed after physically scanning the sensor. A further contrast between real-time CGM and the FreeStyle Libre is the need for real-time CGM systems to be calibrated at regular intervals using finger-stick glucose levels. The FreeStyle Libre device, which uses wired enzyme technology, is factory calibrated and does not need finger-stick glucose calibration during use, with stability of the sensor up to 14 days.
Abbott provided users with the option of direct online purchase of the FreeStyle Libre, without prior healthcare professional approval. This, combined with the relatively low cost and advertising, led to a demand which exceeded the manufacturer's expectations. Shortly after launch, orders were suspended while a new factory was built. In the present review, we aim to explore the reasons underlying the popularity of this device, and discuss the clinical data, accuracy and challenges that this new device brings to diabetes care in the UK. To provide readers with the most up-to-date information we have included both published papers and conference abstracts (Table 1) . Data presented in some conference abstracts are preliminary in nature. Table 1 lists the randomized controlled trials on the FreeStyle Libre device. The largest study is the IMPACT randomized controlled multicentre European trial [11] . That study included 239 participants with well-controlled [HbA 1c ≤59 mmol/mol (7.5%)] Type 1 diabetes and intact awareness of hypoglycaemia, a third of whom used continuous subcutaneous insulin infusion therapy. FreeStyle Libre use was associated with a 38% reduction in time spent in hypoglycaemia (<3.9 mmol/l) with no change in total daily insulin dose. The reduction in hypoglycaemia was achieved within 2 weeks, despite no training on glucose data interpretation and no healthcare professional contact during this period, suggesting that users intuitively understood how to react to the data (Fig. 1) . There was an increase in glucose time in range, combined with a reduction in glycaemic variability. HbA 1c was unchanged.
Randomized controlled trials
FreeStyle Libre users were scanning 15 times/day on average, a behaviour sustained over the 6-month follow-up. FreeStyle Libre utilisation was high at >90% with high treatment satisfaction. It is important to highlight that those with impaired awareness of hypoglycaemia were not included in IMPACT.
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In a randomized, non-masked parallel group study conducted in London by Reddy et al. [12] , the FreeStyle Libre was assessed compared with real-time CGM (Dexcom G5) in people with Type 1 diabetes who had experienced a severe hypoglycaemic event in the last 12 months or had impaired awareness of hypoglycaemia (Gold score ≥4). After a 2-week run-in period, 40 participants using intensified multiple daily injections were randomized to either Dexcom G5 The FreeStyle Libre has also been assessed in people with Type 2 diabetes on intensive insulin therapy in a large multicentre European study of 224 participants [13] . Despite less frequent sensor scans than were seen in the IMPACT study (8 vs 15 per day), time in hypoglycaemia (<3.9 mmol/l) was reduced by 0.47±0.13 h/day compared with a control group, representing a 43% reduction in time spent in hypoglycaemia. HbA 1c was unchanged.
Treatment satisfaction was higher in users and no device-related serious adverse events were reported, suggesting that flash glucose monitoring also offers a suitable replacement for SMBG in those with Type 2 diabetes who are on intensive insulin therapy.
Observational studies Adults
A range of observational studies have evaluated the FreeStyle Libre (Table 1) . Dover et al. [14] prospectively assessed the FreeStyle Libre in 25 participants and described improved glucose control, reduced hypoglycaemia and improved quality of life. The mean HbA 1c of 64 mmol/mol (8.0±0.14%) reduced to 59 mmol/mol (7.5±0.14%) after 16 weeks. Those with a baseline HbA 1c >58 mmol/mol (7.5%) experienced a greater (-0.59±0.15%) reduction. There 
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This article is protected by copyright. All rights reserved. day to 11 scans per day. The authors also commented in their abstract that the device facilitated virtual contact and support.
Children and young adults
Campbell et al. [18] 
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User satisfaction and insights Adults
User feedback on the FreeStyle Libre is generally very positive. Olafsdottir et al. [19] explored treatment experience in 58 adults with Type 1 diabetes. The FreeStyle Libre scored favourably, with scores of 9/10 for 'My experience of the FreeStyle Libre was very positive' and 9.4/10 for 'I would like to use FreeStyle Libre in my daily life'. The participants reported the device was easy to use (9.8/10) and easy and trouble-free to insert (9.1/10) and, importantly, they felt it was easy to interpret information on the FreeStyle Libre screen (9.6/10). The authors also compared their findings for FreeStyle Libre user satisfaction (overall score 82.2-98/100) with their earlier studies of the Dexcom G4 and Enlite sensor which used the same questions (overall score 72.5-90/100 for Dexcom G4 and 42.1-86.1/100 for Enlite).
Ish-Shalom et al. [16] reported their experience in Israel with the FreeStyle Libre. All users (n = 31) were highly satisfied and stated that they would like to use flash glucose monitoring in the future. In addition, users unanimously stated that it was easy to use and painless.
Healthcare professionals reported that the data presentation, particularly the ambulatory glucose profile, was an outstanding tool, enabling better and easier control of glucose levels.
Children/young adults
Families of children who have used the device are generally satisfied. McPhater et al. [20] contacted the families of 19 FreeStyle Libre users. They reported that the sensor was easy to insert and was an easier method of checking glucose than SMBG (preliminary analysis, conference abstract). The majority found the sensor lasted 14 days. Most perceived that glucose control had improved during use as a result of improved awareness of glucose levels,
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Although trend data were useful, most users did not alter self-management as a result.
Confidence in nocturnal glucose control was improved. A quarter of participants did not continue to use the sensors because of limited sensor duration and blood glucose discrepancies compared with SMBG.
Another user evaluation in the paediatric population also described high user satisfaction, with the majority rating the device favourably for sensor application (84.3-92.1%) and sensor wear and use (87.2-100%) when comparing use to SMBG (85.4-97.5%) [21] .
Real-world use of FreeStyle Libre
The manufacturer of the FreeStyle Libre evaluated the association of real-world scanning using the FreeStyle Libre monitor with glucose control measures [22] . In that study, a large number of real-time readers (50 831) with 279 446 sensors (86.4 million monitoring hours by 63.8 million scans) were analysed (Fig. 2) . Users performed an average of 16.3 scans per day [median (interquartile range) 14 (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) ]. Estimated HbA 1c levels decreased (P<0.001) as the scan rate increased, from 64 mmol/mol (8.0%) to 50 mmol/mol (6.7%) from the lowest (mean 4.4 scans/day) to the highest (mean 48.1 scans/day) groups, while time below 3.9, 3.0 and 2.5 mmol/l decreased by 15%, 40% and 49%, respectively (all P<0.001).
Adverse events
As one might expect, most adverse events were related to the medical grade adhesives used to secure the sensor for 14 days. Sensor-wear-related symptoms were recorded as adverse events in the IMPACT trial if the effects were severe and lasted for >7 days, or if the user required prescription medication for the event to resolve [11] . IMPACT reported 13 device-
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This article is protected by copyright. All rights reserved. related adverse events in 10/119 users in the intervention arm, which were related to wearing the sensor, and were categorized as mild (three cases), moderate (four cases) and severe (six cases). Six of 120 participants in the intervention arm and one of 121 participants in the control arm withdrew from the study because of adverse events. For participants with adverse events involving skin symptoms, the symptoms (including severe) were resolved by use of barrier products (e.g. Cavilon spray) or drug therapy (e.g. zinc ointment, Fenistil gel or hydrocortisone cream), or by relocating the device to another area [23] . Investigations have since identified isobornyl acrylate as the likely agent causing contact dermatitis [24] Since completion of the IMPACT trial, minor design changes have been made to the FreeStyle Libre. These changes are expected to improve breathability of the skin that is in contact with the sensor and to facilitate the exclusion of moisture between the sensor-skin interface [23] . During the children's study, five device-related adverse events were reported in five (6%) participants: allergic reaction, blister, pink mark/scabbing and abrasion on sensor removal [21] .
Assessing sensor accuracy
There are no consensus guidelines for the best metric by which to assess the accuracy of realtime CGM and flash glucose monitoring devices. As a result, a variety have been used, the majority of which are affected by glucose excursions, therefore, comparing across studies may lead to misleading conclusions [25] . Ideally different sensors should be compared in the same individual exposed to same glucose fluctuations.
Accuracy of CGM devices is expressed using standards originally designed for assessing the accuracy of SMBG [26] . Numerical accuracy is based on mean or median absolute relative deviation (ARD; sensor glucose-reference glucose/reference glucose*100) and/or
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International Standardization Organization (ISO) criteria [27] . Glucose data are non-normally distributed so the median ARD is usually lower than the mean ARD. In 2013, ISO criteria (ISO: 15197:2013) were drawn up, requiring that 95% of blood glucose results be within ± 0.83 mmol/l of laboratory results at concentrations of <5.6 mmol/l, or within ± 15% of laboratory results at concentrations of ≥5.6 mmol/l [27]. In contrast, clinical accuracy is often expressed using Clarke or consensus error grid analyses [28, 29] . Error grid analyses assign a specific level of clinical risk to any possible error. Each point on the grid (true glucose, measured glucose) is associated with one of five risk levels. In both Clarke and consensus error grids, errors in zones A and B denote minimal risk to the user.
Accuracy of FreeStyle Libre Accuracy in adults
The FreeStyle Libre monitor provides interstitial glucose results without the need for fingerstick glucose calibrations. This removes the risk of sensor inaccuracies attributable to user errors, such as not washing hands before a glucose test or delay in glucose entry [30] .
In a study funded by the manufacturer, Bailey et al. [31] assessed the accuracy of the FreeStyle Libre in 72 study participants with Type 1 or Type 2 diabetes at four clinical sites in the USA. A sensor was inserted at the back of each upper arm for up to 14 days. Three sensor lots were used in the study. There were three scheduled in-clinic visits during the 14-day sensor wear period, where venous blood samples were collected every 15 min over an 8-h period for YSI analyser reference tests (Yellow Springs Instruments, Yellow Springs, OH, USA). At least eight capillary glucose tests, using the glucose meter built into the reader, were required to be performed on each day of the sensor wear, both at home and in the clinic.
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This article is protected by copyright. All rights reserved. The overall mean ARD was 11.4% for sensor results with capillary glucose reference. The overall mean ARD in the clinic alone for sensors' results with capillary glucose reference and with YSI reference was 12.1% and 12%, respectively. Mean ARD was comparable when the reference glucose was <100 mg/dl and >100 mg/dl. Looking at the performance of individual sensors, ~55% appear to have a mean ARD ≤10%, while ~10% of sensors had mean ARD values ≥16%. The percentage of sensor glucose levels in zone A of the Clarke error grid was lower on day 1 (~72%) compared with days 2 to 14 (85% to 89%).
During an independent study, Olafsdottir et al. [19] assessed the accuracy of the FreeStyle Libre device in 58 adults with Type 1 diabetes for 10-14 days and measured capillary blood glucose levels with the HemoCue blood glucose measurement system at least six times a day simultaneously. For the entire study period, the mean ARD was 13.2%. For glucose values <4, 4-10, and >10 mmol/l, the mean ARD was 20.3%, 14.7%, and 9.6%, respectively. 
Accuracy during oral glucose tolerance test
Another study by Fokkert et al. [32] has compared the accuracy of the FreeStyle Libre monitor during 14 days of home use and during an oral glucose tolerance test. Interestingly, they also compared the accuracy of the device when worn in the back of the arm and in the abdomen. The percentage of data points in the zone A of the Clarke error grid was significantly higher when the sensors were worn in the back of the arm (85.5%) compared with the abdomen (64%). Authors found the FreeStyle Libre tended to report lower results in lower glucose ranges, and higher results than expected in the higher ranges. Following a standardized glucose load, a slower rise in glucose level was observed for FreeStyle Libre as compared with reference methods during the first 45-60 min after glucose load ingestion.
Accuracy in children
The accuracy of the FreeStyle Libre in children has been assessed during a multicentre UKbased study [21] . Those aged 4-17 years, with Type 1 or Type 2 diabetes treated with multiple daily injections of insulin or continuous subcutaneous insulin infusion, and monitoring blood glucose >2 times/day were eligible to participate. Participants wore the sensor for up to 14 days and were asked to perform four blood glucose tests daily (FreeStyle Optium test strips; Abbott Diabetes Care), each immediately followed by an interstitial fluid glucose sensor measurement (data masked to participants) to allow comparison of results between sensor and blood glucose. Clarke error grid analysis showed 83.8% of results in zone A and 99.4% of results in zones A and B. Overall, the mean ARD was 13.9% and the median ARD was 10.4%. For paired results at lower glucose concentrations, with capillary glucose <5.5 mmol/l (n=1468), the mean absolute difference was 0.75 mmol/l; for paired results at
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higher glucose concentrations, capillary glucose 5.5-10.0 mmol/L (n=2090), the mean ARD was 13.5%, and at capillary glucose >10.0 mmol/l (n=1935), the mean ARD was 10.6%.
Accuracy in pregnant women
Scott et al. [33] 
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In another study, Bonora et al. [35] The accuracy of the Freestyle Libre, with a mean ARD of 11.4%, is comparable to many commercially available blood glucose meters. Blood glucose meters should fulfil the ISO criteria but when tested independently this was not found to be the case. Ekhlaspour et al. [36] assessed 17 different commercially available glucose meters against the Yellow Springs reference method (YSI 2300) to determine the mean ARD. The accuracy varied widely: mean ARD ranged from 5.6% to 20.8%. Overall, nine of 17 meters assessed had a mean ARD >12%, raising the possibility that some blood glucose meters could potentially be less accurate than the FreeStyle Libre.
Evaluation of FreeStyle Libre with potentially interfering substances
The manufacturer has undertaken tests to evaluate the FreeStyle Libre with 16 potentially interfering substances (Table S1 ) [37] . Testing confirmed no clinically significant interference for the substances tested, with the exception of ascorbic acid and salicylic acid.
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Taking ascorbic acid may falsely raise and salicylic acid may slightly lower sensor glucose readings. The level of inaccuracy depends on the amount of interfering substance. Detailed information is available Table S1 .
Summary of accuracy
In conclusion, FreeStyle Libre appears to have similar accuracy to that of currently available 
Adjunctive vs non-adjunctive use
The term non-adjunctive refers to the use of interstitial glucose data for insulin dosing without the need for additional finger-stick glucose checks. Presently, two glucose monitoring systems are licensed for non-adjunctive use in Europe and the USA: the Dexcom G5 system and FreeStyle Libre system. FreeStyle Libre is designed to replace blood glucose testing in the self-management of diabetes including the dosing of insulin except in three main conditions. These are: during rapidly changing glucose values; to confirm sensor-reported hypoglycaemia or impending hypoglycaemia; and if symptoms do not correspond with the glucose value displayed. Under these circumstances, the manufacturer advises confirmation with a finger-stick glucose level.
Further, Kovatchev et al. [38] using simulation techniques has calculated a minimal accuracy of a mean ARD of ≤10% for real-time CGM to reach sufficient safety when sensor glucose
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This article is protected by copyright. All rights reserved. data are used for insulin-dosing decisions. As outlined in the above accuracy studies, a small number of FreeStyle Libre sensors will have a mean ARD >15% and, unless the user cross checks with finger-stick glucose, it is not possible to know how an individual sensor is performing. The accuracy on day 1 of the sensor is lower than other days. A recent statement from the German Diabetes Society, as well as others, have highlighted pros and cons of using Dexcom G5/FreeStyle Libre in a non-adjunctive manner [39] [40] [41] . FreeStyle Libre users can perform a finger-stick (ideally fasting/when glucose not rapidly changing) to assess sensor accuracy. Also, the Driver and Vehicle Licencing Agency in the UK states that blood rather than interstitial glucose should be checked prior to driving [42] .
Challenges Funding and reimbursement in UK
In November 2017, the FreeStyle Libre became available on prescription in the UK, bringing the latter into line with several other European countries (France, Belgium, Sweden among others) where FreeStyle Libre is reimbursed. NICE has published a 'medtech innovation briefing' on the FreeStyle Libre [43] and has summarized the utility as well as gaps in the evidence base, including the uncertainties around resource impact which depends on the extent to which improved glucose control translates into fewer complications, reduced emergency admissions and less use of glucose test strips. However, in England funding is subject to local approval. Given the financial pressures on the National Health Service, there is concern that variation in local policies for funding will result in inequitable access, further widening variation in diabetes care. In an attempt to overcome this, the Regional Medicine Optimisation Committee has published recommendations for funding in select groups.
(https://www.sps.nhs.uk/articles/regional-medicines-optimisation-committee-freestyle-libreposition-statement/).
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Education
There is a recognized need for healthcare professionals to equip themselves with the skills required to support users of both flash glucose monitoring and real-time CGM [44] .
Healthcare professionals can be reassured that, fundamentally, the skills required to make the most of the data are essentially the same principles as for intensive insulin therapy: aiming for a basal insulin which keeps the glucose relatively stable overnight, and aiming for insulin-carbohydrate ratios which bring the glucose into target by the next meal and insulin sensitivity factors which correct a higher glucose, bringing it into target 4-5 h later without causing hypoglycaemia. In the authors' experience, flash glucose monitoring is an educational tool. Many adjust basal insulin to minimize nocturnal hypoglycaemia and bolus 15-20 min pre-meal to reduce postprandial hyperglycaemia. These behavioural changes reflect the unique insights continuous glucose data provide vs isolated finger-stick glucose levels.
Ambulatory glucose profile
Flash glucose data can be displayed as an ambulatory glucose profile (Figure 3 ). The ambulatory glucose profile displays the data over a 24-h period, with median glucose levels, the 25--75th and 10--90th percentiles, as well as excursions and the tendency for hypo-or hyperglycaemia throughout the day. This display allows ease of hypothesis generation, while eliminating 'noise' from outliers. An expert group in the USA concluded that standardization of CGM data reporting using the ambulatory glucose profile would be of benefit [45] Matthaei et al. [46] have since developed a useful consensus statement on the interpretation of the ambulatory glucose profile.
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Summary and personal perspectives
From the authors' perspective, FreeStyle Libre is a significant advance in the management of diabetes. Many users describe it as 'life changing'. Key advantages and disadvantages are summarized in Table 2 . The FreeStyle Libre allows on-demand access to glucose data with no need for calibration and no risk of alarm fatigue. The sensor needs replaced infrequently and has a accuracy similar to real-time CGM. FreeStyle Libre data can be visualized in multiple devices and platforms as an ambulatory glucose profile to aid pattern recognition and insulin dose adjustment. We encourage appropriate education of both users and healthcare professionals, to harness the full benefits. As a more affordable option for CGM data, we support access to this technology for all people with diabetes who are treated with intensive insulin therapy. Further randomized studies to assess the long-term impact on HbA 1c , particularly in those with high baseline HbA 1c and in specific age groups such as adolescents and young adults are warranted.
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